Biotechnology Value Fund
VC Fund
San Francisco, United States
Biotechnology Value Fund is an evergreen fund specializing in early stage financing. It focuses on undervalued investment
- Total investments:
- 100
- Last investment:
- Lead investor:
- 27%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Biotechnology Value Fund invests in
Stages Biotechnology Value Fund invests in
Countries Biotechnology Value Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Mark Nathan Lampert
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 74 (74%)
- Health Care 46 (46%)
- Therapeutics 34 (34%)
- Pharmaceutical 31 (31%)
- Medical 27 (27%)
Stage
- Post-IPO Equity 36 (36%)
- Series B 24 (24%)
- Series A 14 (14%)
- Series C 8 (8%)
- Venture - Series Unknown 4 (4%)
Country
- United States 64 (64%)
- Switzerland 4 (4%)
- Canada 2 (2%)
- United Kingdom 2 (2%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gorjan Hrustanovic
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
James Kratky
Chief Financial Officer, Chief Compliance Officer
|
Chief Financial Officer, Chief Compliance Officer | Total investments: 0 | Find email | |
|
Mark Nathan Lampert
President, CEO/Founder
|
President, CEO/Founder | Total investments: 2 | Find email | |
Matthew Perry
Portfolio Manager
|
Portfolio Manager | Total investments: 0 | Find email | |
Michael Murray
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rapt Therapeutics
|
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development. | $150M / Post-IPO Equity / Dec 23, 2024 | |
Palvella Therapeutics
|
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | Post-IPO Equity / Dec 13, 2024 | |
Ambrosia Biosciences
|
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $25M / Series A / Dec 10, 2024 | |
Olema Oncology
|
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to designcompounds that are superior to both the current drugs and those in development.Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. | $250M / Post-IPO Equity / Dec 02, 2024 | |
Cidara Therapeutics
|
Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California. | $105M / Post-IPO Equity / Nov 21, 2024 | |
Forte Biosciences
|
Forte Biosciences is a biotechnology company that focuses on dermatology. The company's lead product, FB-401, is a topically applied live biotherapeutic developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases for the treatment of inflammatory skin disease. | $53M / Post-IPO Equity / Nov 20, 2024 | |
Eledon Pharmaceuticals
|
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. | $85M / Post-IPO Equity / Oct 29, 2024 | |
Alpha-9 Oncology
|
Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $175M / Series C / Oct 23, 2024 | |
Inventiva Pharma
|
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $126.1M / Post-IPO Equity / Oct 14, 2024 | |
Bambusa Therapeutics
|
Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies. | $15M / Seed / Sep 09, 2024 | |
| See all 100 investments → | |||
Co-Investors
Biotechnology Value Fund
97 deals together
Biotechnology Value Fund
66 deals together
RA Capital Management
33 deals together
Logos Capital
28 deals together
Janus Henderson Investors
20 deals together
Surveyor Capital
19 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Biotechnology Value Fund invest in?
Biotechnology Value Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 100 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Biotechnology Value Fund?
Public channels for Biotechnology Value Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Biotechnology Value Fund?
The team at Biotechnology Value Fund includes Gorjan Hrustanovic (Managing Director), James Kratky (Chief Financial Officer, Chief Compliance Officer) and Mark Nathan Lampert (President, CEO/Founder), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
